Literature DB >> 11004098

Soluble Fas ligand and soluble Fas in ocular fluid of patients with uveitis.

S Sugita1, C Taguchi, H Takase, K Sagawa, J Sueda, K Fukushi, N Hikita, T Watanabe, K Itoh, M Mochizuki.   

Abstract

AIMS: To investigate the presence of soluble Fas ligand (sFasL) and soluble Fas (sFas) in ocular fluid of patients with uveitis.
METHODS: Samples of aqueous humour (AH, n=17), vitreous fluid (n=9), and serum (n=60) were collected from patients with uveitis which included Behçet's disease, Vogt-Koyanagi-Harada disease, sarcoidosis, human T lymphotropic virus type 1 (HTLV-I) uveitis, sympathetic ophthalmia, HLA-B27 associated acute anterior uveitis, and ocular toxoplasmosis. The AH of patients with age related cataract without uveitis obtained during cataract surgery was used as controls (n=20). The amounts of sFasL and sFas were measured by enzyme linked immunosorbent assay.
RESULTS: Significant amounts of sFasL were detected in AH of patients with age related cataract (non-uveitis group). sFasL was also detected in AH of patients with uveitis, though the amounts were slightly lower than those in the non-uveitis group. On the other hand, the levels of sFas in AH of patients with uveitis were significantly higher than those in controls. As for the disease activity, the levels of sFasL and sFas in the vitreous fluid of patients with active uveitis were significantly higher than those in inactive uveitis. sFasL in the serum of healthy donors and patients with uveitis was below detectable levels, except for patients with HTLV-I uveitis who had significant amounts of sFasL in the serum. The levels of sFas in the serum of patients with Behçet's disease, sarcoidosis, and HTLV-I uveitis were significantly higher than those of healthy donors.
CONCLUSIONS: sFasL is present in the AH of non-uveitic eyes with age related cataract. Intraocular levels of sFasL and sFas are significantly increased in uveitis, particularly in active uveitis. These data suggest that intraocular sFasL and sFas may have a regulatory role in uveitis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11004098      PMCID: PMC1723273          DOI: 10.1136/bjo.84.10.1130

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  29 in total

1.  Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing.

Authors:  I Cascino; G Fiucci; G Papoff; G Ruberti
Journal:  J Immunol       Date:  1995-03-15       Impact factor: 5.422

2.  Fas ligand-induced apoptosis as a mechanism of immune privilege.

Authors:  T S Griffith; T Brunner; S M Fletcher; D R Green; T A Ferguson
Journal:  Science       Date:  1995-11-17       Impact factor: 47.728

3.  Divergent induction of apoptosis and IL-8 secretion in HT-29 cells in response to TNF-alpha and ligation of Fas antigen.

Authors:  M T Abreu-Martin; A Vidrich; D H Lynch; S R Targan
Journal:  J Immunol       Date:  1995-11-01       Impact factor: 5.422

4.  A role for CD95 ligand in preventing graft rejection.

Authors:  D Bellgrau; D Gold; H Selawry; J Moore; A Franzusoff; R C Duke
Journal:  Nature       Date:  1995-10-19       Impact factor: 49.962

Review 5.  Apoptosis in the pathogenesis and treatment of disease.

Authors:  C B Thompson
Journal:  Science       Date:  1995-03-10       Impact factor: 47.728

6.  Expression of the Fas ligand in cells of T cell lineage.

Authors:  T Suda; T Okazaki; Y Naito; T Yokota; N Arai; S Ozaki; K Nakao; S Nagata
Journal:  J Immunol       Date:  1995-04-15       Impact factor: 5.422

Review 7.  The Fas death factor.

Authors:  S Nagata; P Golstein
Journal:  Science       Date:  1995-03-10       Impact factor: 47.728

8.  Fas-mediated cytotoxicity by freshly isolated natural killer cells.

Authors:  H Arase; N Arase; T Saito
Journal:  J Exp Med       Date:  1995-03-01       Impact factor: 14.307

9.  Expression of the functional soluble form of human fas ligand in activated lymphocytes.

Authors:  M Tanaka; T Suda; T Takahashi; S Nagata
Journal:  EMBO J       Date:  1995-03-15       Impact factor: 11.598

10.  Metalloproteinase-mediated release of human Fas ligand.

Authors:  N Kayagaki; A Kawasaki; T Ebata; H Ohmoto; S Ikeda; S Inoue; K Yoshino; K Okumura; H Yagita
Journal:  J Exp Med       Date:  1995-12-01       Impact factor: 14.307

View more
  8 in total

1.  Ocular immune privilege in the year 2010: ocular immune privilege and uveitis.

Authors:  Andrew W Taylor; Henry J Kaplan
Journal:  Ocul Immunol Inflamm       Date:  2010-12       Impact factor: 3.070

2.  Transfection of apoptosis related gene Fas ligand in human hepatocellular carcinoma cells and its significance in apoptosis.

Authors:  Jun Chen; Xian-Shi Su; Yong-Fang Jiang; Guo-Zhong Gong; Yu-Huang Zheng; Gui-Yuan Li
Journal:  World J Gastroenterol       Date:  2005-05-07       Impact factor: 5.742

3.  Proapoptotic CD95L levels in normal human serum and sera of breast cancer patients.

Authors:  Vicente Olimón-Andalón; Adriana Aguilar-Lemarroy; Sarah Ratkovich-González; Aida Uribe-López; Ignacio Mariscal-Ramírez; Raúl Delgadillo-Cristerna; Pablo Ortiz-Lazareno; Georgina Hernández-Flores; Ruth de Celis; Alejandro Bravo-Cuellar; Luis F Jave-Suárez
Journal:  Tumour Biol       Date:  2015-01-04

Review 4.  Immune mechanisms in inflammatory and degenerative eye disease.

Authors:  Victor L Perez; Rachel R Caspi
Journal:  Trends Immunol       Date:  2015-05-13       Impact factor: 16.687

5.  Factors affecting pain in patients undergoing bilateral cataract surgery.

Authors:  Pei Liu; Shuoji Zhang; Zhao Geng; Rongdi Yuan; Jian Ye
Journal:  Int Ophthalmol       Date:  2019-10-17       Impact factor: 2.031

6.  Opposing roles for membrane bound and soluble Fas ligand in glaucoma-associated retinal ganglion cell death.

Authors:  Meredith S Gregory; Caroline G Hackett; Emma F Abernathy; Karen S Lee; Rebecca R Saff; Andreas M Hohlbaum; Krishna-Sulayman L Moody; Maura W Hobson; Alexander Jones; Paraskevi Kolovou; Saoussen Karray; Andrea Giani; Simon W M John; Dong Feng Chen; Ann Marshak-Rothstein; Bruce R Ksander
Journal:  PLoS One       Date:  2011-03-29       Impact factor: 3.240

7.  Ocular Inflammation and Treatment Emergent Adverse Events in Retinal Gene Therapy.

Authors:  Neesurg Mehta; Deborah A Robbins; Glenn Yiu
Journal:  Int Ophthalmol Clin       Date:  2021-07-01

8.  Galectin-9-mediated protection from allo-specific T cells as a mechanism of immune privilege of corneal allografts.

Authors:  Machiko Shimmura-Tomita; Mingcong Wang; Hiroko Taniguchi; Hisaya Akiba; Hideo Yagita; Junko Hori
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.